Osteoarthritis (OA) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Osteoarthritis (OA) is a multifactorial disease process whereby progressive musculoskeletal pain and limitation in the movement are accompanied by the loss of articular cartilage, sclerotic and cystic changes in local bone, and osteophyte formation. OA is a joint condition whose presentation so differs between men and women in its attributes that both prevention activities and treatment would benefit from recognition of this dimorphism. These structural and anatomic differences between the sexes are observed early and later in life. Articular cartilage of the distal femur is less thick in girls and women than in boys and men—pain in the affected joint, including thickening of the joint capsule and the formation of osteophytes. ~43.3% have pain, aching, or stiffness osteoarthritis on most days. Reports of pain increased with age up to 68% of patients and were higher in blacks than in whites and in women than in men, 47.6% and 37.4%, respectively.

 

In the US, the total prevalent pool for Osteoarthritis (OA) ranges from 20 MN to 25 MN, among which more than 40% are being diagnosed with knee osteoarthritis (OA).

 

The competitive landscape of Osteoarthritis (OA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Osteoarthritis (OA) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Osteoarthritis (OA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Osteoarthritis (OA)– Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          EP-104IAR        Eupraxia Pharmaceuticals Inc.   Phase 2

2          pentosan polysulfate sodium      Paradigm Biopharmaceuticals            Phase 3

3          JointStem         Nature Cell Co. Ltd.       Phase 2

4          LY3016859       Eli Lilly and Company    Phase 2

5          OLP-1002         OliPass Corporation      Phase 2

6          Adalimumab      AbbVie  Phase 2

7          Fasinumab        Regeneron Pharmaceuticals      Phase 3

8          Axolotl Ambient Axolotl Biologix  Phase 2

9          YYD302            Yooyoung Pharmaceutical Co., Ltd.        Phase 2

10        GRT6005          Tris Pharma, Inc.           Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more